Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04045613
Title	Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)
Acronym	FIDES-02
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Basilea Pharmaceutica
Indications	bladder urothelial carcinoma
Therapies	Derazantinib Atezolizumab + Derazantinib
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS